FK614|cas:193012-35-0|西域试剂

FK614,99.82%

产品编号：Bellancom-101292| CAS NO：193012-35-0| 分子式：C₂₁H₂₃Cl₂N₃O₃S| 分子量：468.40

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-101292		￥5500.00	杭州北京（现货）
Bellancom-101292		￥9400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FK614

产品介绍

FK614 是一种口服活性非噻唑烷二酮 (TZD) 型选择性 PPARγ 调节剂 (SPPARM)。FK614 是一种 PPARγ 激动剂，显示出强大的抗糖尿病活性。FK614 在脂肪细胞分化的各个阶段对 PPARγ 的激活有不同的影响。FK614 可用于研究高血糖、高甘油三酯血症、糖耐量异常和 2 型糖尿病。

生物活性

FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes.

体外研究

FK614 (0.1~10000 nM; 24 hours; CV-1 cells) activates PPARγ-dependent transcription in a concentration-dependent manner. FK614 (0~0.1 μM; 5 days; 3T3-L1 adipocytes) makes triglyceride content increased in a concentration-dependent manner. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation.
FK614 is an insulin sensitizer potentially for treatment of postherpetic neuralgia. FK614 is a non-TZD insulin sensitizer.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level.
FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	db/db Mice
Dosage:	0.1~10 mg/kg
Administration:	P.o.
Result:	Improved the impaired glucose tolerance.

Animal Model:	db/db Mice
Dosage:	0.32~3.2 mg/kg
Administration:	P.o.
Result:	Dose-dependently reduced plasma glucose level.

体内研究

FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level.
FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	db/db Mice
Dosage:	0.1~10 mg/kg
Administration:	P.o.
Result:	Improved the impaired glucose tolerance.

Animal Model:	db/db Mice
Dosage:	0.32~3.2 mg/kg
Administration:	P.o.
Result:	Dose-dependently reduced plasma glucose level.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (213.49 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1349 mL	10.6746 mL	21.3493 mL
5 mM	0.4270 mL	2.1349 mL	4.2699 mL
10 mM	0.2135 mL	1.0675 mL	2.1349 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.34 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.34 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。